NOVEL COMPOUNDS FOR MODULATING NEOVASCULARISATION AND METHODS OF TREATMENT USING THESE COMPOUNDS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Nov 1, 2012
app pub date -
Nov 4, 2010
filing date -
Nov 4, 2009
priority date (Note) -
Abandoned
status (Latency Note)
![]() |
A preliminary load of PAIR data current through [] has been loaded. Any more recent PAIR data will be loaded within twenty-four hours. |
PAIR data current through []
A preliminary load of cached data will be loaded soon.
Any more recent PAIR data will be loaded within twenty-four hours.
![]() |
Next PAIR Update Scheduled on [ ] |

Importance

US Family Size
|
Non-US Coverage
|
Abstract
The invention relates to a method for modulating neovascularisation of a tissue in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a compound or a combination of compounds selected from an isolated nucleic acid molecule comprising a gene selected from the group consisting of RIKEN c DNA S9430020K01, Agtrl1, Apelin, Stabilin 1, Stabilin 2, TNFaip8l1, TNFaip8 and FGD5, and homologues thereof; a gene product encoded by said genes, or encoded by homologues of these genes, and functional fragments thereof; an antibody or derivative thereof directed against a gene product of said genes, or encoded by homologues of these genes, and functional fragments thereof, said derivative preferably being selected from the group consisting of scFv fragments, Fab fragments, chimeric antibodies, bifunctional antibodies, intrabodies, and other antibody-derived molecules; an antisense molecule, in particular an antisense RNA or antisense oligodeoxynucleotide, an RNAi molecule (siRNA or mi RNA) or a ribozyme capable of binding under stringent hybridization conditions to a gene or an m RNA gene product of said genes and homologues thereof; a small molecule interfering with the biological activity of a gene product of said genes and homologues thereof, and a (glycol)protein, a hormone and other biologically active compounds capable of interacting with said genes and homologues thereof or with a gene product thereof.
First Claim
all claims..Other Claims data not available
Family

- 15 United States
- 10 France
- 8 Japan
- 7 China
- 5 Korea
- 2 Other
Patent Owner(s)
Patent Owner | Address | |
---|---|---|
ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM | 3015 GE ROTTERDAM |
International Classification(s)

- 2010 Application Filing Year
- A61K Class
- 10962 Applications Filed
- 7633 Patents Issued To-Date
- 69.64 % Issued To-Date
Inventor(s)
Inventor Name | Address | # of filed Patents | Total Citations |
---|---|---|---|
Duckers, Henricus Johannes | Delft, NL | 4 | 30 |
# of filed Patents : 4 Total Citations : 30 |
Cited Art Landscape
- No Cited Art to Display

Patent Citation Ranking
- 6 Citation Count
- A61K Class
- 12.01 % this patent is cited more than
- 13 Age
Forward Cite Landscape
- No Forward Cites to Display

Maintenance Fees
Fee | Large entity fee | small entity fee | micro entity fee | due date |
---|
Fee | Large entity fee | small entity fee | micro entity fee |
---|---|---|---|
Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |
Full Text

Legal Events
- No Legal Status data available.

Matter Detail

Renewals Detail
